» Authors » Richard J Buick

Richard J Buick

Explore the profile of Richard J Buick including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 89
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kwok H, Buick R, Kuehn D, Gormley J, Doherty D, Jaquin T, et al.
Mol Cancer . 2011 Dec; 10:147. PMID: 22168338
Background: Proteolytic enzymes have been implicated in driving tumor progression by means of their cancer cell microenvironment activity where they promote proliferation, differentiation, apoptosis, migration, and invasion. Therapeutic strategies have...
2.
Camper N, Byrne T, Burden R, Lowry J, Gray B, Johnston J, et al.
J Immunol Methods . 2011 Jul; 372(1-2):30-41. PMID: 21782818
Monoclonal antibodies and derivative formats such as Fab' fragments are used in a broad range of therapeutic, diagnostic and research applications. New systems and methodologies that can improve the production...
3.
Kwok H, Scott C, Snoddy P, Buick R, Johnston J, Olwill S
Res Vet Sci . 2010 Jan; 89(1):41-7. PMID: 20096429
The incidence of bovine tuberculosis (bTB) is increasingly giving rise to large economic losses in the agricultural industry. The current methods used for detection and control of bTB (skin test...
4.
Caswell J, Snoddy P, McMeel D, Buick R, Scott C
Protein Expr Purif . 2009 Nov; 70(2):143-50. PMID: 19883766
The use of Escherichia coli protein expression systems has many benefits, including the ease of propagation, amounts of protein that can be generated and cost. However, this host has some...
5.
Burden R, Snoddy P, Buick R, Johnston J, Walker B, Scott C
Mol Cancer Ther . 2008 Mar; 7(3):538-47. PMID: 18347141
Human cathepsin L along with cathepsin S, K, and V are collectively known as cathepsin L-like proteases due to their high homology. The overexpression and aberrant activity of each of...
6.
Scott C, Marouf W, Quinn D, Buick R, Orr S, Donnelly R, et al.
Pharm Res . 2007 Aug; 25(1):135-46. PMID: 17674157
Purpose: To prepare a nanoparticulate formulation expressing variable peripheral carboxyl density using non-endcapped and endcapped poly(lactide-co-glycolide), conjugated to antibodies recognising the siglec-7 receptor, which is expressed on most acute myeloid...
7.
Orr S, Morgan N, Buick R, Boyd C, Elliott J, Burrows J, et al.
J Biol Chem . 2006 Dec; 282(6):3418-22. PMID: 17138568
CD33-related Siglecs (sialic acid-binding immunoglobulin-like lectins) 5-11 are inhibitory receptors that contain a membrane proximal ITIM (immunoreceptor tyrosine-based inhibitory motif) (I/V/L/)XYXX(L/V), which can recruit SHP-1/2. However, little is known about...
8.
McCarron P, Olwill S, Marouf W, Buick R, Walker B, Scott C
Mol Interv . 2006 Jan; 5(6):368-80. PMID: 16394252
Immunotherapeutics represent the largest group of molecules currently in development as new drug entities. These versatile molecules are being investigated for the treatment of a range of pathological conditions including...